clinical trial · NCT05936268
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
Changchun GeneScience Pharmaceutical Co., Ltd.·phase2·completed·n = 106
Acute GoutGout FlareGenakumab for injectionColchicine
brief summary
To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy
started
Jul 21, 2023
primary completion
Feb 28, 2024
completion
Feb 28, 2024
last updated
Nov 8, 2024
detailed description
Phase 2， randomized, open lable, multi-center, active controlled study. Patients are randomized to Genakumab 200mg single injection group or Etoricorxib 120mg qd po.(until remission or intorlerance, no longer than 8 days) group.
official title
A Randomized, Open Lable, Multi-center, Active Competitor Phase 2 Study for Evaluating Efficacy and Safety of Genakumab for Injection as First Line Therapy in Patients With Gout Flare
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol